Which Drug Next? Sequential Therapy for Osteoporosis.

BOOKMARK THIS ARTICLE FOR FUTURE REFERENCE

The proliferation of drugs with unique modes of action for treating osteoporosis has been most welcome. Fear of complications , even though rare, associated with long term bisphosphonates, changed prescribing patterns. The Bisphosphonates are stored in bone for years. Drugs not stored in bone; e.g. abaloparatide, teriparatide, denosumab, and romosozumab have expanded our armamentarium for treating osteoporosis but have brought new challenges. Bone accrued during treatment with the latter 3 drugs, and perhaps abaloparatide, is lost rapidly after their withdrawl due to rebound increase in bone resorption. Treatment with these drugs must be followed by administration of an anti-resorptive agent.. The article by Kendler et al. in this issue of JCEM reports alendronate preserves bone accrued during administration of denosumab.

Click here to read the full article @ The Journal of clinical endocrinology and metabolism